#USA #IDC MarketScape #Evanston #ZS #Life Sciences R&D

ZS Achieves Leader Status in IDC MarketScape 2026

On September 14, 2026, ZS, a globally recognized management consulting and technology firm, was honored with the title of Leader in the IDC MarketScape report for Life Science Research and Development (R&D) Real-World Data (RWD) and Real-World Evidence (RWE). This assessment highlights ZS's exceptional capabilities across various platforms, technology solutions, and consulting services, solidifying its position at the forefront of the life sciences sector.

The IDC MarketScape evaluation methodology is rigorous and extensive, assessing organizations based on their capabilities and strategies concerning RWD and RWE. ZS's latest recognition comes on the heels of its acknowledgment as a Leader in the IDC MarketScape Worldwide Life Sciences R&D Strategic Consulting Services earlier in May 2026. This consecutive acknowledgment underscores the firm's robust track record in providing innovative solutions that enable life sciences organizations to better navigate complex regulatory and medical decision-making processes.

Insights from Leadership

Rohan Fernando, managing principal of ZS's life sciences R&D and medical practice, stated, "Life sciences organizations are increasingly searching for connected approaches to evidence and decision-making throughout the product life cycle. As the industry strives to maximize value from real-world data, companies require efficient methods to convert evidence into actionable insights. Through integrated evidence planning and connected evidence-generation capabilities, we assist clients in transforming RWD into decision-quality insights that drive regulatory, medical, and business outcomes. We take great pride in being recognized by IDC MarketScape as a Leader in this critical area."

Strengths of ZS

The IDC MarketScape identified several strengths that differentiate ZS in the competitive landscape:
1. Integrated Medical Evidence Practice: ZS has continued to enhance its integrated Medical Evidence practice, which connects medical RWD with Health Economics and Outcomes Research (HEOR) strategies to accelerate decision-making processes.
2. Evidence Generation Process: The firm seamlessly links evidence generation with downstream dissemination, ensuring that the data produced effectively supports publications, congress strategies, and field medical execution.
3. Innovative Platforms: ZS has developed the ZAIDYN Medical platform, which offers various modules such as OLI for Opinion Leader Intelligence, CGI for Care Gap Intelligence, SMI for Scientific Medical Intelligence, MCE for Medical Customer Engagement, and POI for Patient Outcomes Impact analysis. This comprehensive platform provides clients with valuable insights and aids in effective decision-making.
4. AI-Driven Patient Radar Platform: One of ZS's cutting-edge offerings is the AI-enabled Patient Radar platform, designed to identify hard-to-reach rare-disease patients and physicians. This initiative has led to the successful diagnosis of 26 new patients within a mere 12 months for a rare disease organization, demonstrating the platform’s impact on patient care.
5. European Impact: ZS Data Nexus represents a proprietary, regulatory-grade RWD access platform and has become the first RWE solution to attain Europrivacy certification, thereby reinforcing ZS's commitment to data integrity and compliance in Europe.
6. Client Satisfaction and Retention: With an impressive 90% Net Promoter Score (NPS) and a 97% retention rate for RWD/RWE initiatives, ZS showcases its capability and trustworthiness as a partner in the life sciences sector.
7. Digital Integrated Evidence Planning: ZS's unique Integrated Evidence Planning (IEP) capability, delivered through the ZS Evidence Pro platform, has substantially optimized development times, decreasing the span from 4-5 months per IEP to generating over 30 IEPs in just 10 weeks, while enjoying a 75% acceptance rate for over 20 protocol recommendations.

Conclusion

As life sciences companies face mounting pressures to produce robust evidence that supports regulatory, medical, and commercial decisions, the integration of strategy, data, technology, and scientific expertise becomes crucial. ZS is committed to empowering clients to transform real-world data into actionable evidence, thereby accelerating meaningful impact throughout the product life cycle. This recent accolade from IDC MarketScape reinforces ZS's leading role in the industry and sets the stage for continued innovation and excellence in life sciences R&D.

For more information regarding ZS's capabilities in evidence and medical affairs, please visit www.zs.com.

About ZS

Founded in 1983, ZS is a management consulting and technology firm dedicated to making a significant impact on the world. With a team of over 15,000 experts across more than 40 global offices, ZS combines data, science, technology, and human creativity to deliver transformational outcomes.

About IDC MarketScape

IDC MarketScape provides a competitive assessment framework of technology and service suppliers in various markets. Its methodologies incorporate both qualitative and quantitative evaluations, offering a comprehensive analysis of suppliers' positions in the market. This framework aids technology buyers in understanding the strengths and weaknesses of current and potential suppliers.